Bayer takes up Activaero's inhaler tech
This article was originally published in Clinica
Pulmonary drug delivery specialist Activaero has inked a licensing agreement with German drugs giant Bayer Healthcare to develop new inhaled therapies. The deal includes an upfront fee for Gemünden, Germany-based Activaero, and milestone payments that are tied to an option. Financial details were not disclosed. Activaero CEO Dr Gerhard Scheuch described the deal as a "major milestone", and believes "pulmonary administration of drugs has a huge potential for the treatment of lung diseases and diseases which start in the lung". The company's lead technology is the Akita, an inhalation system that is tailored to an individual's breathing pattern in order to deliver the optimum drug dosage (see a profile of Activaero in Clinica's Medtech Ventures No 17).
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.